MyFinsight
Home
Blog
About
OnKure Therapeutics, Inc. (OKUR)
OnKure Therapeutics, Inc. (OKUR)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$25,604K
Free Cash flow
-$10,357K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from the issuance of cl...
Share-based compensation expense
Accounts payable, accrued and ot...
Others
Negative Cash Flow Breakdown
Net loss
Purchases of marketable securiti...
Payment of issuance costs associ...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Direct program expense
-
-
28,373
-
Indirect program expense
-
-
1,923
-
Workforce salaries and benefits
-
-
16,301
-
Share-based compensation expense
-
-
11,633
-
General corporate expenses
-
-
4,720
-
Interest and other expense
-
-
8
-
Interest income
-
-
3,441
-
Adjustments and reconciling items
-
-
3,441
-
Net loss
-15,346
-15,157
-13,503
-14,699
Share-based compensation expense
3,049
2,780
3,019
2,961
Depreciation and amortization
87
104
104
108
Amortization of right-of-use asset - operating
101
99
98
96
Loss on disposal of property and equipment
-
-
-4
-2
Accretion of discount on marketable securities, net
30
-
-
-
Prepaid and other assets
-89
-281
763
5
Accounts payable, accrued and other liabilities
1,832
-905
-305
-1,364
Lease liabilities
-136
-140
-138
-136
Other long-term liabilities
-
-
-28
0
Net cash used in operating activities
-10,354
-12,938
-11,512
-13,037
Purchases of marketable securities
9,867
-
-
-
Purchases of property and equipment
3
5
9
6
Net cash used in investing activities
-9,870
-5
-9
-6
Payment of issuance costs associated with the concurrent financing
-
-
0
0
Proceeds from the issuance of class a common stock and pre-funded warrants in connection with 2026 private placement
4,000
145,999
-
-
Payment of reverse recapitalization transaction costs
-
-
0
0
Payment of issuance costs associated with the 2026 private placement
9,583
-
-
-
Proceeds from sale of stock under the employee stock purchase plan
203
-
240
-
Net cash provided by (used in) financing activities
-5,380
145,999
240
0
Net increase (decrease) in cash and cash equivalents
-25,604
133,056
-11,281
-13,043
Cash and cash equivalents, beginning of period
192,106
59,050
70,331
110,761
Cash and cash equivalents, end of period
166,502
192,106
59,050
70,331
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net increase
(decrease) in cash and cash...
-$25,604K
(6.51%↑ Y/Y)
Share-based compensation
expense
$3,049K
(-46.06%↓ Y/Y)
Accounts payable,
accrued and other...
$1,832K
(163.70%↑ Y/Y)
Amortization of right-of-use
asset - operating
$101K
(-46.56%↓ Y/Y)
Prepaid and other assets
-$89K
(91.58%↑ Y/Y)
Depreciation and
amortization
$87K
(-62.98%↓ Y/Y)
Proceeds from the
issuance of class a common...
$4,000K
Proceeds from sale of
stock under the...
$203K
Net cash used in
operating activities
-$10,354K
(62.04%↑ Y/Y)
Net cash used in
investing activities
-$9,870K
(-31738.71%↓ Y/Y)
Net cash provided by
(used in) financing...
-$5,380K
(-6887.01%↓ Y/Y)
Canceled cashflow
$5,158K
Canceled cashflow
$4,203K
Net loss
-$15,346K
(50.99%↑ Y/Y)
Purchases of marketable
securities
$9,867K
Purchases of property and
equipment
$3K
(-90.32%↓ Y/Y)
Payment of issuance
costs associated with...
$9,583K
Lease liabilities
-$136K
(48.09%↑ Y/Y)
Accretion of discount on
marketable securities, net
$30K
Buy us a coffee